On September 2, 2021 Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, reported that the Company will participate in the following upcoming virtual investor conferences in September (Press release, Decibel Therapeutics, SEP 2, 2021, View Source [SID1234587177]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate at:

H.C. Wainwright’s 23rd Annual Global Investment Conference: Presentation on Monday, September 13, 2021 at 7:00 a.m. E.T.
Baird’s 2021 Global Healthcare Conference: Fireside chat on Tuesday, September 14, 2021 at 4:20 p.m. E.T. The session will be available via live webcast to conference attendees.
Management will participate in investor meetings at:

Citi’s 16th Annual BioPharma Virtual Conference: Investor meetings on Friday, September 10, 2021.
SVB Leerink’s CybeRx Series: Neuromuscular, Rare Diseases and Genetic Medicines 1×1 Event on Wednesday, September 22, 2021 and Thursday, September 23, 2021.
A webcast of the H.C. Wainwright fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at View Source An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.